The Pro- and Antiangiogenic Effects of Statins

ABSTRACT

Clinical studies indicate that 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy has a cardiovascular protective activity that may result from an improvement in endothelial function. Experimental studies have shown that statins protect against ischaemia-reperfusion injury of the heart and stimulate the growth of new blood vessels in ischemic limbs of normocholesterolemic animals. The mechanisms underlying these serum lipid-independent effects of statins are not completely understood, but there is increasing evidence that they improve endothelial function through molecular mechanisms that mediate an increase in endothelium-derived nitric oxide. Recent research has revealed a link between statins and the serine/threonine protein kinase Akt that regulates multiple angiogenic processes in endothelial cells, including the generation of nitrous oxide. In contrast to these data, it has also been reported that higher doses of statins inhibit endothelial cell migration and angiogenesis. Thus, further studies on the actions of statins may lead to the identification of new pharmacological targets for the control of blood vessel growth.

KEYWORDS

Statin - angiogenesis - Akt - NO

REFERENCES

• 1 Maron D J, Fazio S, Linton M F. Current perspectives on statins.  Circulation. 2000;  101 207-213
• 2 West of Scotland Coronary Prevention Study Group . Influence of pravastatin and plasma lipids of clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).  Circulation. 1998;  97 1440-1445
• 3 Dupuis J, Tardif J C, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial.  Circulation. 1999;  99 3227-3233
• 4 Muramatsu J, Kobayashi A, Hasegawa N, Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin.  Atherosclerosis. 1997;  130 179-182
• 5 Egashira K, Hirooka Y, Kai H et al.. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.  Circulation. 1994;  89 2519-2524
• 6 Leung W H, Lau C P, Wong C K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients.  Lancet. 1993;  341 1496-1500
• 7 Kaesemeyer W H, Caldwell R B, Huang J, Caldwell R W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions.  J Am Coll Cardiol. 1999;  33 234-241
• 8 Williams J K, Sukhova G K, Herrington D M, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.  J Am Coll Cardiol. 1998;  31 684-691
• 9 Jorge P A. Osaki MR, de Almeida E. Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin.  Clin Exp Pharmacol Physiol. 1997;  24 948-953
• 10 Endres M, Laufs U, Huang Z et al.. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.  Proc Natl Acad Sci U S A. 1998;  95 8880-8885
• 11 Lefer A M, Campbell B, Shin Y-K, Scalia R, Hayward R, Lefer D J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts.  Circulation. 1999;  100 178-184
• 12 Lefer A M, Lefer D J. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion.  Cardiovasc Res. 1996;  32 743-751
• 13 Osborne J A, Siegman M J, Sedar A W, Mooers S U, Lefer A M. Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits.  Am J Physiol. 1989;  256(3 Pt 1) C591-C597
• 14 Ikeda Y, Young L H, Lefer A M. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats.  J Cardiovasc Pharmacol. 2003;  41 649-656
• 15 Wolfrum S, Grimm M, Heidbreder M et al.. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase.  J Cardiovasc Pharmacol. 2003;  41 474-480
• 16 Bell R M, Yellon D M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.  J Am Coll Cardiol. 2003;  41 508-515
• 17 Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis.  Circ Res. 2002;  90 1243-1250
• 18 Semenza G L. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance.  J Clin Invest. 2001;  108 39-40
• 19 Kureishi Y, Luo Z, Shiojima I et al.. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.  Nat Med. 2000;  6 1004-1010
• 20 Sata M, Nishimatsu H, Suzuki E et al.. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia.  FASEB J. 2001;  15 2530-2532
• 21 Weis M, Heeschen C, Glassford A J, Cooke J P. Statins have biphasic effects on angiogenesis.  Circulation. 2002;  105 739-745
• 22 Llevadot J, Murasawa S, Kureishi Y et al.. HMG-CoA reductase inhibitor mobilizes bone-marrow derived endothelial progenitor cells.  J Clin Invest. 2001;  108 399-405
• 23 Nishikawa H, Miura S I, Zhang B et al.. Pravastatin promotes coronary collateral circulation in patients with coronary artery disease.  Coron Artery Dis. 2002;  13 377-381
• 24 Pourati I, Kimmelstiel C, Rand W, Karas R H. Statin use is associated with enhanced collateralization of severely diseased coronary arteries.  Am Heart J. 2003;  146 876-881
• 25 Sata M, Nishimatsu H, Osuga J I et al.. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis.  Hypertension. 2004;  43 1214-1220
• 26 Feleszko W, Mlynarczuk I, Nowis D. In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor.  FEBS Lett. 2001;  503 219-220
• 27 Feleszko W, Balkowiec E, Sieberth E et al.. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis.  Int J Cancer. 1999;  81 560-567
• 28 Kawata S, Yamasaki E, Nagase T et al.. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.  Br J Cancer. 2001;  84 886-891
• 29 Okamoto T, Yamagishi S, Inagaki Y et al.. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.  Faseb J. 2002;  16 1928-1930
• 30 Urbich C, Dernbach E, Zeiher A M, Dimmeler S. Double-edged role of statins in angiogenesis signaling.  Circ Res. 2002;  90 737-744
• 31 Dimmeler S, Aicher A, Vasa M et al.. HMG-CoA-reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.  J Clin Invest. 2001;  108 391-397
• 32 Walter D H, Rittig K, Bahlmann F H et al.. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells.  Circulation. 2002;  105 3017-3024
• 33 Aicher A, Heeschen C, Mildner-Rihm C et al.. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells.  Nat Med. 2003;  9 1370-1376
• 34 Haendeler J, Hoffmann J, Diehl J F et al.. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells.  Circ Res. 2004;  94 768-775
• 35 Assmus B, Urbich C, Aicher A et al.. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes.  Circ Res. 2003;  92 1049-1055
• 36 Vasa M, Fichtlscherer S, Adler K et al.. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.  Circulation. 2001;  103 2885-2890
• 37 Gerber H-P, McMurtrey A, Kowalski J et al.. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation.  J Biol Chem. 1998;  273 30336-30343
• 38 Papapetropoulos A, Fulton D, Mahboubi K et al.. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/Survivin pathway.  J Biol Chem. 2000;  275 9102-9105
• 39 Fulton D, Gratton J P, McCabe T J et al.. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.  Nature. 1999;  399 597-601
• 40 Morales-Ruiz M, Fulton G, Sowa G et al.. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt.  Circ Res. 2000;  86 892-896
• 41 Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand J L, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins.  Circ Res. 2001;  89 866-873
• 42 Servant G, Weiner O D, Herzmark P, Balla T, Sedat J W, Bourne H R. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis.  Science. 2000;  287 1037-1040
• 43 Skaletz-Rorowski A, Lutchman M, Kureishi Y, Lefer D J, Faust J R, Walsh K. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells.  Cardiovasc Res. 2003;  57 253-264
• 44 Brown D A, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts.  J Biol Chem. 2000;  275 17221-17224
• 45 Manes S, Mira E, Gomez-Mouton C et al.. Membrane raft microdomains mediate front-rear polarity in migrating cells.  EMBO J. 1999;  18 6211-6220
• 46 Baumann C A, Ribon V, Kanzaki M et al.. CAP defines a second signalling pathway required for insulin-stimulated glucose transport.  Nature. 2000;  407 202-207
• 47 Muller G, Jung C, Wied S, Welte S, Jordan H, Frick W. Redistribution of glycolipid raft domain components induces insulin-mimetic signaling in rat adipocytes.  Mol Cell Biol. 2001;  21 4553-4567
• 48 Furuchi T, Anderson R G. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK).  J Biol Chem. 1998;  273 21099-21104
• 49 Rizzo M A, Kraft C A, Watkins S C, Levitan E S, Romero G. Agonist-dependent traffic of raft-associated ras and raf-1 is required for activation of the mitogen-activated protein kinase cascade.  J Biol Chem. 2001;  276 34928-34933
• 50 Zundel W, Swiersz L M, Giaccia A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide.  Mol Cell Biol. 2000;  20 1507-1514
• 51 Laufs U, Liao J K. Targeting Rho in cardiovascular disease.  Circ Res. 2000;  87 526-528
• 52 Laufs U, Liao J K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase.  J Biol Chem. 1998;  273 24266-24271
• 53 Laufs U, Endres M, Stagliano N et al.. Neuroprotection mediated by changes in the endothelial actin cytoskeleton.  J Clin Invest. 2000;  106 15-24
• 54 Wagner A H, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.  Arterioscler Thromb Vasc Biol. 2000;  20 61-69
• 55 Wassmann S, Laufs U, Muller K et al.. Cellular antioxidant effects of atorvastatin in vitro and in vivo.  Arterioscler Thromb Vasc Biol. 2002;  22 300-305
• 56 Feron O, Dessy C, Desager J P, Balligand J L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.  Circulation. 2001;  103 113-118
• 57 Campbell M, Allen W E, Sawyer C, Vanhaesebroeck B, Trimble E R. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways.  Circ Res. 2004;  , In press
• 58 Verma S, Rao V, Weisel R D et al.. Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells.  J Surg Res. 2004;  119 66-71
• 59 Vincent L, Chen W, Hong L et al.. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect.  FEBS Lett. 2001;  495 159-166
• 60 Vincent L, Soria C, Mirshahi F et al.. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models.  Arterioscler Thromb Vasc Biol. 2002;  22 623-629
• 61 Vincent L, Albanese P, Bompais H et al.. Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.  Thromb Haemost. 2003;  89 530-537
• 62 Morikawa S, Takabe W, Mataki C et al.. Global analysis of RNA expression profile in human vascular cells treated with statins.  J Atheroscler Thromb. 2004;  11 62-72
• 63 Asakage M, Tsuno N H, Kitayama J et al.. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest.  Anticancer Drugs. 2004;  15 625-632
• 64 Park H J, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper J B. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.  Circ Res. 2002;  91 143-150
• 65 Frick M, Dulak J, Cisowski J et al.. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells.  Atherosclerosis. 2003;  170 229-236